Short Sellers Become More Selective on Major Biotechs
The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Many companies are being discussed as Zika virus winners, but the reality is that many of them are so small or have sketchy histories. This is why we are featuring seven notable…
The May 13 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
May 19, 2016: Here are four stocks trading with heavy volume among 81 equities making new 52-week lows in Thursday’s session. NYSE decliners led advancers by nearly 2 to 1 while Nasdaq…
The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
Gilead Sciences saw a sell-off after the company posted less than favorable earnings, but one analyst thinks that investors have spoken too soon.
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital and Whiting Petroleum.
Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in earnings per share (EPS) on $7.79 billion in revenue compared to consensus…
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also help generate billions for drug manufacturers. Pharmaceutical companies generate an estimated $300…
In a recent report, UBS made some significant changes to its Equity Focus list. The analysts look to go a touch more aggressive with the new additions.
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.
Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.